Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies

Tavotek | May 25, 2020

Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's DuoBody® technology platform against disease relevant target antigens. Tavotek employs TavoSelect™, with proprietary VHO phage and Fab phage libraries, to efficiently identify lead molecules for generation of bispecific antibodies against validated target combinations. The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions. "The research partnership with Genmab aligns with Tavotek's mission to develop life-changing therapies for patients with significant unmet medical needs, especially in the field of immunology," said Dr. Mann Fung, Chief Executive Officer of Tavotek Biotherapeutics. "Despite the availability of various biologics for many autoimmune and inflammatory diseases, there are patients who do not respond to existing therapies and have become intolerant due to adverse side effects from many of these treatments. We believe our novel bispecific antibody will help many patients and have a beneficial impact on patient care of autoimmune disorders. Our Fc engineering technology can further optimize pharmacokinetics and tissue specificity of the bispecific antibodies." The DuoBody® technology is a proprietary platform of Genmab A/S of Denmark. It is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious, and central nervous system disease. This platform has been successfully used in many Genmab internal or partnered investigational therapies.

Spotlight

This infographis related to the best biotech mining Microbiome.

Spotlight

This infographis related to the best biotech mining Microbiome.

Related News

MEDTECH

Evaxion Biotech Identifies Gonorrhea as Second Bacterial Product Target

Evaxion Biotech | July 04, 2022

The clinical-stage biotechnology company Evaxion Biotech A/S which specializes in the creation of AI-driven immunotherapies, said today that it has chosen gonorrhea as its second bacterial target for the Company's EVX-B2 vaccine product candidate. Evaxion has opted to create a preventative vaccination against Gonorrhea, a sexually transmitted disease (STD) that has fast acquired antibiotic resistance, as its second bacterial target. Based on preliminary results in pre-clinical models, we think Evaxion's unique AI platform EDEN has discovered promising antigen candidates for the vaccine. “We are very pleased to announce that our AI platform EDEN has demonstrated the ability to identify two promising protective antigens based on very encouraging results in the pre-clinical model. Gonorrhea represents a large unmet medical need. We believe that with this vaccine, patients will be able to produce antibodies against bacterial infection - minimizing the risk of infection” Lars Staal Wegner, CEO

Read More

CELL AND GENE THERAPY

PINNACLE FERTILITY PARTNERS WITH IGENOMIX AS THEIR EXCLUSIVE GENETICS LABORATORY AND GENETIC COUNSELING PROVIDER

Igenomix | June 08, 2022

Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services. Continuing Pinnacle's commitment to collaborative medical leadership and patient-first care, this strategic partnership was the result of the Medical Council's collective determination and offers patients an increased opportunity to find success in their family-building journey. Our Medical Director Council extensively studied the science behind major genetic labs to determine which would provide us with the best possible data to make key decisions. Bringing Igenomix on as our exclusive genetics provider for Pinnacle Fertility clinics continues to ensure that we meet our single guiding principle which is to provide the best patient outcomes possible." Dr. Richard Marrs, Chief Medical Director for Pinnacle Fertility. With more than 15 years of experience, Igenomix is the global leader in reproductive genetics and focuses on quality, safety, and science to help healthcare professionals and patients detect genetic abnormalities before treatment, avoid implantation failure, and ensure patients achieve a healthy pregnancy. Pinnacle Fertility continues to set the standard in fertility care by bringing leading technology, integration and innovation to its suite of family building services. Partnerships with companies like Igenomix, who are committed though-leaders like we are, benefit our patients and those seeking to grow their families with the help world-class reproductive genetic testing and counseling services." Andrew Mintz, CEO at Pinnacle Fertility. PGT is an elective treatment option that can be used to identify embryos at risk of having a specific genetic or chromosomal condition and is available for patients at all fertility clinics within the Pinnacle network. Igenomix offers the most comprehensive portfolio of infertility treatments for genetics and was the first organization to launch non-invasive PGT-A services. Patients who choose to use PGT as part of their treatment plan receive complementary pre- and post-test genetic counseling to help guide and educate them on their options and results. Bringing Igenomix onboard is an exciting opportunity for our patients to seamlessly have access to genetic testing and counseling services, such as PGT at our fertility clinics, The genetic counselors are perfectly integrated into our programs and champion our patients' success like we do." Dr. Priya Maseelall from Reproductive Gynecology and Infertility Patients electing to use PGT, undergo in vitro fertilization (IVF) to create embryos, and then cells are removed from each embryo for genetic testing. Embryos with normal results are selected to be transferred into the uterus in hopes of achieving a pregnancy and delivering a child without a genetic condition. By utilizing PGT, genetic diseases can be prevented. In addition, studies have shown that PGT can not only improve success rates but also provide optimism and peace of mind during pregnancy and after birth. About Pinnacle Fertility Pinnacle Fertility is the nation's fastest-growing physician-centric fertility care platform, supporting high-performing fertility clinics and comprehensive fertility service providers nationwide. Under a united mission of fulfilling dreams by building families, Pinnacle clinics offer innovative technology and processes, compassionate patient care, and comprehensive fertility treatment services, ensuring families receive a high-touch experience on their path to parenthood. About Igenomix Igenomix is a global leader in reproductive genetic testing with laboratories in 23 countries and assisting hundreds of thousands of patients per year worldwide. As part of Vitrolife Group, the company is recognized for its R&D expertise and quality of service. In the US, Igenomix has proven to be the best-in-class when comes to credibility, consistency on their results, automatization of their laboratories and the most important, patient care.

Read More

MEDICAL

Invenshure Launches MEKanistic Therapeutics™

Invenshure | June 03, 2022

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity generally associated with current kinase inhibitors. MEKanistic is using cutting edge computational tools to not only understand how these pathways work, but also design medications that perfectly fit within those sites to inhibit the spread of cancer. We have two unique advantages. First, our lead drug's expanded therapeutic window means dramatically reduced side effects for cancer patients. Second, when it's paired with existing cancer therapies, our drug makes them much more effective, We are excited to partner with Pfizer Global R&D veterans, Drs. Leopold and Whitehead, to propel this important technology forward into clinical trials." Danny Cunagin, CEO of MEKanistic. MEKanistic will be launching a round of funding in the coming weeks to support the translation of our lead candidate (MTX-531) towards IND approval later this year with the anticipation of initiation of Phase 1 clinical trials in early 2023. MTX-531's initial application targets head and neck cancers with 900,000 cases worldwide per year. Ultimately, this drug has possible future applications for colon/rectal, esophageal, pancreatic, and some breast cancers. Our work could potentially impact millions of people each year." Chief Scientific Officer, Dr. Sebolt-Leopold. About Invenshure™ Invenshure is a venture studio that scours university research labs for novel and disruptive technologies ready for commercialization. Invenshure partners with top scientists, physicians, and researchers from the most trusted institutions in healthcare and technology. The company focuses on high-growth sectors including biotech, genomics, healthcare IT, diagnostics, cloud computing technologies, and wireless technologies.

Read More